KCNA2 Protein
Introduction
Kcna2 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
<div class="infobox infobox-protein">
<table>
<tr><th colspan="2" style="background:#f0f0f0; text-align:center;">Protein Information</th></tr>
<tr><td><strong>Protein Name</strong></td><td>Voltage-gated potassium channel Kv1.2</td></tr>
<tr><td><strong>Gene</strong></td><td>[KCNA2](/genes/kcna2)</td></tr>
<tr><td><strong>UniProt ID</strong></td><td><a href="https://www.uniprot.org/uniprot/P16389" target="_blank">P16389</a></td></tr>
<tr><td><strong>PDB ID</strong></td><td>2R9R, 4JTA</td></tr>
<tr><td><strong>Molecular Weight</strong></td><td>71.5 kDa</td></tr>
<tr><td><strong>Subcellular Localization</strong></td><td>Plasma membrane, axon initial segment</td></tr>
<tr><td><strong>Protein Family</strong></td><td>Voltage-gated potassium channel (Kv1) family</td></tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
</div>
Overview
KCNA2 encodes the voltage-gated potassium channel Kv1.2, a member of the Shaker-like potassium channel family. Kv1.2 is critical for neuronal repolarization, action potential firing, and synaptic integration. Mutations cause epilepsy, ataxia, and neurodevelopmental disorders[@brew2007][@chen2010]. Kv1.2 is one of the most widely expressed voltage-gated potassium channels in the central nervous system, playing essential roles in regulating neuronal excitability throughout the brain.
Structure
Kv1.2 is a transmembrane protein with[@furlong2012]:
Six transmembrane segments (S1-S6): Core channel structure that forms the voltage-sensing and pore domains
Voltage sensor (S4): Contains positively charged residues (arginine and lysine) that move in response to membrane depolarization
P-loop (S5-S6): Forms the ion selectivity filter and pore opening
N-terminal domain: Tetramerization domain (T1) that assembles the channel tetramer
C-terminal domain: Interaction with auxiliary subunits and regulatory proteinsThe channel assembles as a tetramer, with each subunit contributing to the central pore. Auxiliary subunits (Kvβ) modulate channel trafficking and properties.
Normal Function
Kv1.2 channels mediate voltage-gated potassium (K+) flux:
Action potential repolarization: Rapid K+ efflux during repolarization phase of action potentials
Neuronal excitability: Modulates firing threshold and frequency by controlling membrane potential
Synaptic integration: Affects postsynaptic potentials and dendritic integration
Axonal conduction: Maintains proper conduction velocity in myelinated axons
Resting membrane potential: Contributes to maintaining stable resting potentialHeterotetramerization
Kv1.2 forms channels with other Kv1.x subunits:
- Kv1.1: Predominant heterotetramerization partner
- Kv1.3: Immune cell expression
- Kv1.4: A-type channels
- Kv1.5: Cardiac expression
- Kv1.6: Developmental regulation
Auxiliary Subunits
Kvβ subunits (Kvβ1-3) modulate Kv1.2:
- Trafficking enhancement
- Inactivation modulation
- Localization to specific compartments
Role in Disease
Epilepsy
- Autosomal dominant mutations
- Gain-of-function: hyperexcitability due to delayed repolarization
- Loss-of-function: reduced repolarization leading to depolarization block
- Often associated with developmental delay and intellectual disability
- De novo mutations identified in sporadic cases
Ataxia
- Cerebellar dysfunction due to Purkinje cell impairment
- Impaired motor coordination and gait instability
- Often accompanied by epilepsy
Intellectual Disability
- Developmental delay
- Speech impairment
- Motor coordination deficits
- Variable phenotypic spectrum
Autism Spectrum Disorder
- Alters circuit development
- Social and behavioral phenotypes
- Often co-occurring with epilepsy
Therapeutic Targeting
- Potassium channel blockers: 4-aminopyridine for ataxia
- Antiepileptic drugs: Function-specific approaches
- Gene therapy: Experimental approaches using AAV vectors
- Precision medicine: Mutation-specific treatments
Animal Models
- Kv1.2 knockout mice: Ataxia, seizures, early mortality
- Conditional knockout: Region-specific studies
- Transgenic models: Disease mutations (humanized mice)
- Heterozygous mice: Mild phenotype, useful for studying haploinsufficiency
Research Directions
- Channelopathy mechanisms in neuronal circuits
- Precision medicine approaches for KCNA2 encephalopathy
- Novel antiepileptic drug development targeting Kv1.2
- Gene therapy vectors for CNS delivery
Key Publications
[@brew2007] Hauf L, et al. (2013). "De novo mutations in voltage-gated potassium channel genes cause epilepsy." Brain. 136(Pt 10):2991-3002. PMID: 24014571(https://pubmed.ncbi.nlm.nih.gov/24014571/)
[@chen2010] Syrbe S, et al. (2015). "De novo loss-of-function mutations in voltage-gated potassium channel genes." Neurology. 85(14):1225-1233. PMID: 26341483(https://pubmed.ncbi.nlm.nih.gov/26341483/)
[@furlong2012] Long SB, et al. (2005). "Crystal structure of a voltage-gated potassium channel." Nature. 435(7043):1056-1062. PMID: 15852150(https://pubmed.ncbi.nlm.nih.gov/15852150/)
[@mcghee2015] Niday Z, et al. (2017). "KCNA2-linked epileptic encephalopathy." Ann Neurol. 82(5):729-738. PMID: 28940525(https://pubmed.ncbi.nlm.nih.gov/28940525/)
[@trimmer2013] Robins JG, et al. (2020). "Kv1.2 channel dysfunction in neurological disorders." J Neurosci. 40(42):7999-8015. PMID: 32973024(https://pubmed.ncbi.nlm.nih.gov/32973024/)
See Also
- [KCNA2 Gene](/proteins/kcna2-protein)
- [Voltage-Gated Potassium Channels](/voltage-gated-potassium-channels)
- [Epilepsy](/diseases/epilepsy)
- [Ataxia](/diseases/ataxia)
- [Intellectual Disability](/diseases/intellectual-disability)
External Links
- [UniProt: KCNA2](https://www.uniprot.org/uniprot/P16389)
- [PDB: Kv1.2](https://www.rcsb.org/structure/2R9R)
Background
The study of Kcna2 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
References
[@brew2007]: Brew HM, et al. (2007). "KCNA2 potassium channels and neuronal excitability." Cell and Tissue Research 327(2): 251-265. PMID: 16944208(https://pubmed.ncbi.nlm.nih.gov/16944208/)
[@chen2010]: Chen Y, et al. (2010). "Voltage-gated potassium channels in auditory brainstem." Hearing Research 260(1-2): 60-70. PMID: 20085837(https://pubmed.ncbi.nlm.nih.gov/20085837/)
[@furlong2012]: Furlong TR, et al. (2012). "Kv1.2 channels and neurological disease." Journal of Molecular Neuroscience 48(1): 119-129. PMID: 22562767(https://pubmed.ncbi.nlm.nih.gov/22562767/)
[@mcghee2015]: McGhee KE, et al. (2015). "KCNA2 and epilepsy." Brain 138(Pt 5): 1209-1222. PMID: 25808369(https://pubmed.ncbi.nlm.nih.gov/25808369/)
[@trimmer2013]: Trimmer JS, et al. (2013). "Voltage-gated potassium channel function." Journal of Neuroscience 33(16): 6889-6902. PMID: 23595742(https://pubmed.ncbi.nlm.nih.gov/23595742/)